Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926 Approval was based on CAPItello-291, a randomized, double-blind, ...
Fresenius Kabi has announced the availability of Fulvestrant Injection 250mg/5mL prefilled syringe that is stable at room temperature. The product is bioequivalent to Faslodex (AstraZeneca).
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...
(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO) "This approval is an important advancement for women with metastatic breast cancer, where the ...
We previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor–positive metastatic breast cancer who had been ...
HERTFORDSHIRE, England and PITTSBURGH, Sept. 17, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose ...
(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY), an integrated pharmaceutical company, announced the launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose syringe, a therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results